Neumora Therapeutics, Inc. (NMRA)
$0.37-15.91%Close
SELLCRISIS · day 35
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $69M
- Beta
- 2.98
- P/E (TTM)
- -0.30
- Short % float
- 10.74%
- Days to cover
- 2.7
- SI change
- -4.1%
- 1W
- -21.28%
- 1M
- -63.00%
- vs SPY 1W
- -21.70%
- vs SPY 1M
- -65.06%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 15
- VALUE
- 29
- GROWTH
- 47
- GARP
- 6
- TYPE
- Value / Recovery
Composite of Value · Growth · GARP
ROIC-145.4%
REV YoY-
ROE-242.3%
EPS YoY-
ROA-169.9%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-0.30
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B1.54
P/FCF-
EV/EBITDA0.23
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E0.76
ALTMAN Z-
CURR RATIO4.50
ND/EBITDA-
BETA2.98
Company news
FAQ
- What is LOPJLB’s current signal on NMRA?
- LOPJLB’s latest quantitative signal on Neumora Therapeutics, Inc. Common Stock (NMRA) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is NMRA in?
- Neumora Therapeutics, Inc. Common Stock (NMRA) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Neumora Therapeutics, Inc. Common Stock (NMRA) do?
- Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the …